

## Datasheet: MCA401

<b>Description:</b>	MOUSE ANTI INFLUENZA A MATRIX PROTEIN
<b>Specificity:</b>	INFLUENZA A MATRIX PROTEIN
<b>Format:</b>	Purified
<b>Product Type:</b>	Monoclonal Antibody
<b>Clone:</b>	GA2B
<b>Isotype:</b>	IgG1
<b>Quantity:</b>	1 mg

## Product Details

### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry			▪	
Immunohistology - Frozen			▪	
Immunohistology - Paraffin	▪			
ELISA			▪	
Immunoprecipitation			▪	
Western Blotting	▪			
Immunofluorescence	▪			1/100

Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.

<b>Target Species</b>	Viral
<b>Product Form</b>	Purified IgG - liquid
<b>Preparation</b>	Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant.
<b>Buffer Solution</b>	Phosphate buffered saline
<b>Preservative Stabilisers</b>	0.09% Sodium Azide
<b>Approx. Protein</b>	IgG concentration 1.0 mg/ml

## Concentrations

**Immunogen** Influenza A / Puerto Rico / 8 / 34 (H1N1) and A/Bangkok / 1 / 79 (H3N2) viruses.

## External Database Links

### UniProt:

[P03485](#) [Related reagents](#)

[P03487](#) [Related reagents](#)

### Entrez Gene:

[956527](#) M1 [Related reagents](#)

**RRID** AB\_322157

**Fusion Partners** Spleen cells from immunised BALB/c mice were fused with cells of the P3 Ag8.653 mouse myeloma cell line.

**Specificity** **Mouse anti Influenza A matrix protein 1 antibody, clone GA2B** recognizes an epitope within the influenza A matrix protein 1. In both strains of virus used as immunogen to isolate clone GA2B, the matrix protein 1 is a 252 amino acid, highly conserved viral protein playing a crucial role in replication.

Mouse anti Influenza A matrix protein 1 antibody, clone GA2B can be used in influenza A IFA typing in conjunction with [Mouse anti Influenza A matrix protein, clone AA5H](#).

**Purity** >90% IgG content as established by SDS PAGE

## References

1. Latham, T. & Galarza, J.M. (2001) Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. [J Virol. 75 \(13\): 6154-65.](#)
2. Zhirnov, O.P. & Klenk, H.D. (1997) Histones as a target for influenza virus matrix protein M1. [Virology. 235 \(2\): 302-10.](#)
3. Viemann, D. *et al.* (2011) H5N1 virus activates signaling pathways in human endothelial cells resulting in a specific imbalanced inflammatory response. [J Immunol. 186 \(1\): 164-73.](#)
4. Yamamoto, Y. *et al.* (2008) Avian influenza virus (H5N1) replication in feathers of domestic waterfowl. [Emerg Infect Dis. 14: 149-51.](#)
5. Doucet, J.D. *et al.* (2011) Endogenously expressed matrix protein M1 and nucleoprotein of influenza A are efficiently presented by class I and class II major histocompatibility complexes. [J Gen Virol. 92 \(Pt 5\): 1162-71.](#)
6. Tanimura N *et al.* (2006) Pathology of fatal highly pathogenic H5N1 avian influenza virus infection in large-billed crows (*Corvus macrorhynchos*) during the 2004 outbreak in Japan. [Vet Pathol. 43 \(4\): 500-9.](#)
7. Kirkeby, S. *et al.* (2009) Infection with human H1N1 influenza virus affects the expression of sialic acids of metaplastic mucous cells in the ferret airways. [Virus Res. 144: 225-32.](#)
8. Pauli, E.K. *et al.* (2008) Influenza A virus inhibits type I IFN signaling via NF-kappaB-dependent induction of SOCS-3 expression. [PLoS Pathog. 4\(11\): e1000196.](#)

9. Eierhoff, T. *et al.* (2010) The epidermal growth factor receptor (EGFR) promotes uptake of influenza A viruses (IAV) into host cells. [PLoS Pathog. 6. pii: e1001099.](#)
10. Wang, D. *et al.* (2010) The lack of an inherent membrane targeting signal is responsible for the failure of the matrix (M1) protein of influenza A virus to bud into virus-like particles. [J Virol. 84: 4673-81.](#)
11. Kang, S.M. *et al.* (2009) Induction of long-term protective immune responses by influenza H5N1 virus-like particles. [PLoS One. 4: e4667.](#)
12. Luig, C. *et al.* (2010) MAP kinase-activated protein kinases 2 and 3 are required for influenza A virus propagation and act via inhibition of PKR. [FASEB J. 24: 4068-77.](#)
13. Schmolke, M. *et al.* (2009) Essential impact of NF-kappaB signaling on the H5N1 influenza A virus-induced transcriptome. [J Immunol. 183: 5180-9.](#)
14. Reinhardt, J. and Wolff, T. (2000) The influenza A virus M1 protein interacts with the cellular receptor of activated C kinase (RACK) 1 and can be phosphorylated by protein kinase C. [Vet Microbiol. 74: 87-100.](#)
15. Das, S.C. *et al.* (2012) The Highly Conserved Arginine Residues at Positions 76 through 78 of Influenza A Virus Matrix Protein M1 Play an Important Role in Viral Replication by Affecting the Intracellular Localization of M1. [J Virol. 86: 1522-30.](#)
16. Liu, Y.V. *et al.* (2011) Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV. [Vaccine. 29: 6606-13.](#)
17. Moncorgé, O. *et al.* (2013) Investigation of influenza virus polymerase activity in pig cells. [J Virol. 87 \(1\): 384-94.](#)
18. Khapersky, D.A. *et al.* (2012) Influenza A virus inhibits cytoplasmic stress granule formation. [FASEB J. 26: 1629-39.](#)
19. Friesenhagen, J. *et al.* (2012) Highly pathogenic avian influenza viruses inhibit effective immune responses of human blood-derived macrophages. [J Leukoc Biol. 92: 11-20.](#)
20. Londrigan, S.L. *et al.* (2015) Infection of Mouse Macrophages by Seasonal Influenza Viruses Can Be Restricted at the Level of Virus Entry and at a Late Stage in the Virus Life Cycle. [J Virol. 89 \(24\): 12319-29.](#)
21. Sadewasser, A. *et al.* (2017) Quantitative proteomic approach identifies Vpr binding protein as novel host factor supporting influenza A virus infections in human cells. [Mol Cell Proteomics. Mar 13. pii: mcp.M116.065904. doi: 10.1074/mcp.M116.065904. \[Epub ahead of print\]](#)
22. Liu, Y.V. *et al.* (2015) Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets. [Vaccine. 33 \(18\): 2152-8.](#)
23. Herrmann, V.L. *et al.* (2015) Cytotoxic T cell vaccination with PLGA microspheres interferes with influenza A virus replication in the lung and suppresses the infectious disease. [J Control Release. 216: 121-31.](#)
24. Huang, M.T. *et al.* (2015) DcR3 suppresses influenza virus-induced macrophage activation and attenuates pulmonary inflammation and lethality. [J Mol Med \(Berl\). 93 \(10\): 1131-43.](#)
25. Al-Mubarak, F. *et al.* (2015) Identification of morphological differences between avian influenza A viruses grown in chicken and duck cells. [Virus Res. 199: 9-19.](#)
26. Yang, C.H. *et al.* (2017) Influenza A virus upregulates PRPF8 gene expression to increase virus production. [Arch Virol. 162 \(5\): 1223-35.](#)
27. Smith, G.E. *et al.* (2017) Neuraminidase-based recombinant virus-like particles protect

against lethal avian influenza A(H5N1) virus infection in ferrets. [Virology. 509: 90-97.](#)  
28. Usui, T. *et al.* (2020) Outbreaks of highly pathogenic avian influenza in zoo birds caused by HA clade 2.3.4.4 H5N6 subtype viruses in Japan in winter 2016. [Transbound Emerg Dis. 67 \(2\): 686-697.](#)

---

<b>Storage</b>	Store at +4°C or at -20°C if preferred. This product should be stored undiluted. Storage in frost free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
<b>Guarantee</b>	12 months from date of despatch
<b>Health And Safety Information</b>	Material Safety Datasheet documentation #10040 available at: 10040: <a href="https://www.bio-rad-antibodies.com/uploads/MSDS/10040.pdf">https://www.bio-rad-antibodies.com/uploads/MSDS/10040.pdf</a>
<b>Regulatory</b>	For research purposes only

---

## Related Products

### Recommended Secondary Antibodies

Goat Anti Mouse IgG (STAR77...)	<a href="#">HRP</a>
Rabbit Anti Mouse IgG (STAR12...)	<a href="#">RPE</a>
Rabbit Anti Mouse IgG (STAR8...)	<a href="#">DyLight@800</a>
Goat Anti Mouse IgG (STAR76...)	<a href="#">RPE</a>
Goat Anti Mouse IgG (STAR70...)	<a href="#">FITC</a>
Goat Anti Mouse IgG (H/L) (STAR117...)	<a href="#">Alk. Phos.</a> , <a href="#">DyLight@488</a> , <a href="#">DyLight@680</a> , <a href="#">DyLight@800</a> , <a href="#">FITC</a> , <a href="#">HRP</a>
Rabbit Anti Mouse IgG (STAR9...)	<a href="#">FITC</a>
Goat Anti Mouse IgG (Fc) (STAR120...)	<a href="#">FITC</a> , <a href="#">HRP</a>
Goat Anti Mouse IgG IgA IgM (STAR87...)	<a href="#">Alk. Phos.</a> , <a href="#">HRP</a>
Rabbit Anti Mouse IgG (STAR13...)	<a href="#">HRP</a>

<b>North &amp; South America</b>	Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: <a href="mailto:antibody_sales_us@bio-rad.com">antibody_sales_us@bio-rad.com</a>	<b>Worldwide</b>	Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: <a href="mailto:antibody_sales_uk@bio-rad.com">antibody_sales_uk@bio-rad.com</a>	<b>Europe</b>	Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: <a href="mailto:antibody_sales_de@bio-rad.com">antibody_sales_de@bio-rad.com</a>
----------------------------------	---	------------------	---	---------------	---

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://www.bio-rad-antibodies.com/datasheets)

'M367655:200529'

Printed on 23 Mar 2021